Pharmaceutical Contract Manufacturing Market – Global Forecast to 2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical
Contract Manufacturing Global Market – Forecast to 2025” report
has been added to ResearchAndMarkets.com’s offering.

The Pharmaceutical contract manufacturing global market is expected to
grow at mid-single-digit CAGR to reach $95,904.9 million by 2025.

Globally, pharmaceutical markets are showing rapid growth and in the
coming years are expected to evolve further in the field of research and
development, manufacturing and formulation, due to a rise in population,
the increasing incidence of disease, rising healthcare expenditures,
collaborations, merger, and acquisitions. Pharmaceutical companies are
increasing their dependence on contract manufacturing organizations
because they lack well-equipped manufacturing facilities, advanced
technologies, high containment capabilities – or, though they have the
facilities, they are outsourcing due to insufficient time, and in order
to have backup. This trend is favoring contract manufacturing service
providers and is expected to increase their share in the pharmaceutical
manufacturing market.

Contract pharmaceutical manufacturing services are mainly focused on the
manufacturing of Active Pharmaceutical Ingredients (API) and Finished
Dosage Formulations (FDF). One of the major reasons for the increase in
synthetic API market is the availability of small molecule drugs for all
the major diseases and a large number of small molecule drugs in the
pipeline, which is expected to enter the market in coming years.

Pharmaceutical contract manufacturing market based on product is
segmented into API manufacturing and FDF manufacturing. API
manufacturing market holds the largest share in 2018 and is expected to
grow at mid-single-digit CAGR from 2018 to 2025 due to government
initiatives, increase in a number of API manufacturers, increasing
availability of APIs for all the diseases, aging population, rise in
chronic diseases, research and manufacturing of new drugs and demand for
generics.

FDF manufacturing is the fastest growing segment with strong CAGR from
2018 to 2025, due to the high profit margins for pharma contract
manufacturers and most of the CMO companies in APAC regions are shifting
from API to FDF manufacturing.

Key Topics Covered:

1 Executive Summary

2 Introduction

2.1 Key Takeaways

2.2 Scope Of The Report

2.3 Report Description

2.4 Markets Covered

2.5 Stakeholders

2.6 Research Methodology

3 Market Analysis

3.1 Introduction

3.2 Market Segmentation

3.3 Factors Influencing Market

3.3.1 Drivers And Opportunities

3.3.1.1 Increased Trend Of Outsourcing

3.3.1.2 High Uptake Of Small Molecules Across Diverse Therapeutics

3.3.1.3 Patent Expiration Of Small Molecules Drugs

3.3.1.4 Advanced Technologies In API And FDF Manufacturing

3.3.1.5 Increasing Deals And Investments

3.3.1.6 Generics Drive Injectable Market Opportunity

3.3.1.7 Increasing Chronic And Autoimmune Diseases

3.3.1.8 Increase In Geriatric And Aged Population

3.3.2 Restraints And Threats

3.3.2.1 Contamination In The Manufacturing

3.3.2.2 Pricing Pressure For Pharmaceutical Contract Manufacturing

3.3.2.3 Requirement Of Highly Skilled Technicians

3.3.2.4 Increasing Biologics Approvals And Adoption In Disease Management

3.3.2.5 Stringent Regulatory Requirements

3.4 Regulatory Affairs

3.4.1 International Organization For Standardization

3.4.1.1 ISO 9001: 2015 Quality Management System

3.4.1.2 ISO 14644-1 Clean Room Standards

3.5 Porter’s Five Force Analysis

3.6 Supply Chain Analysis

3.7 Market Share Analysis By Major Players

3.7.1 Pharmaceutical Contract Manufacturing Global Market Share Analysis

3.7.2 Market Share Analysis Of API Manufacturing By Major Players

3.7.3 Market Share Analysis Of Fdf Manufacturing By Major Players

3.8 Technological Advancements

3.8.1 Advanced Technologies For API Manufacturing

3.8.2 Advanced Technologies For Fdf Manufacturing

3.9 Differentiated Capabilities

3.9.1 HPAPI

3.9.1.1 Selected Top Selling HPAPI

3.9.2 Continuous Flow Manufacturing

3.9.3 Cryogenic Manufacturing Process

3.10 Controlled Substance API Contract Manufacturing Market

3.11 Patent Expiry And Anda Approvals

3.12 Drug Master Filing (DMF)

3.13 Collaboration Between Pharmaceutical Companies And Contract
Manufacturers

3.14 Companies Acquisition, Merger And Investments

3.15 API Pricing

3.16 Global Pharmaceutical API CMO Production Volume

3.17 Cost Of Manufacturing Facility

3.18 FDA Approved Manufacturing Facility

3.19 Notice Of Inspectional Observations (Form 483)

3.20 China V/S India: Pharmaceutical Contract Manufacturing Market

3.20.1 India

3.20.2 China

3.21 Pharmaceutical Contract Manufacturers Revenue And Capabilities Table

4 Pharmaceutical Contract Manufacturing Global Market, By Product

4.1 Introduction

4.2 API Manufacturing

4.2.1 Branded API Manufacturing

4.2.2 Generic API Manufacturing

4.3 Finished Dosage Form (FDF) Manufacturing

4.3.1 Solid Dosage Forms

4.3.2 Injectables Dosage Forms

4.3.3 Semisolid, Liquid And Gaseous Dosage Forms

5 Pharmaceutical Contract Manufacturing Global Market, By Phase

5.1 Introduction

5.2 Clinical Manufacturing

5.3 Commercial Manufacturing

6 Pharmaceutical Contract Manufacturing Global Market, By
Application

6.1 Introduction

6.2 Oncology

6.3 Central Nervous System

6.4 Cardiovascular Disorders

6.5 Infectious Diseases

6.6 Pulmonary Disorders

6.7 Metabolic Disorders

6.8 Gastrointestinal Disorders

6.9 Musculoskeletal Disorders

6.1 Genitourinary Disorders

6.11 Endocrinology

6.12 Other Applications

7 Regional Analysis

7.1 Introduction

7.2 North America

7.2.1 U.S.

7.2.2 Rest Of North America

7.3 Europe

7.3.1 Germany

7.3.2 France

7.3.3 Italy

7.3.4 Rest Of Europe

7.4 APAC

7.4.1 China

7.4.2 India

7.4.3 Japan

7.4.4 Rest Of Apac

7.5 RoW

7.5.1 Brazil

7.5.2 Rest Of LATAM

7.5.3 Middle East & Others

8 Competitive Landscape

8.1 Introduction

8.2 Acquisition, Merger & Collaboration

8.3 Expansion And Investment

8.4 Regulatory Approval

8.5 Service Launch And Others

9 Major Companies

9.1 Abbvie Inc.

9.2 Aenova Holding Gmbh

9.3 Albany Molecular Research Inc.

9.4 Almac Group

9.5 Cambrex Corporation

9.6 Famar S.A.

9.7 GlaxoSmithKline Plc

9.8 Lonza Group Ltd

9.9 Thermo Fisher Scientific (Patheon N.V.)

9.1 Pfizet Inc (Pfizer Centerone)

9.11 Recipharm AB

9.12 Wuxi Sta Pharmaceuticals Ltd (Wuxi Apptec)

Companies Mentioned

• Aarthi Drugs Ltd.
• Abbvie Contract Manufacturing
• Accupac, Inc. (J.H Whitney Capital Partners Llc)
• Acic Pharmaceutical Inc.
• Aenova Holding Gmbh
• Aesica Pharmaceuticals Ltd (Consort Medical)
• Ajinomoto Bio-Pharma Services
• Akorn, Inc.
• Albany Molecular Research Inc. (Carlyle Group & Gtcr)
• Alcami Corporation
• Alliance Contract Pharma Llc
• Almac Group
• Alpex Pharma S.A.
• Ambio Pharma
• Ampac Fine Chemicals
• A.M.S.A. S.P.A.
• Amr Pharma India Private Limited
• Ani Pharmaceuticals, Inc.
• Ardena Group
• Artesan Pharma Gmbh
• Asymchem Laboratories, Inc.
• Avara Pharmaceutical Services
• Bachem Holding AG
• Biocon Limited
• Biomaxpharma
• Cadila Pharmaceuticals Ltd.
• Cambrex Corporation
• Cerbios Pharma S.A.
• Chambio Co., Ltd.
• Chemcon Gmbh
• China Chemical & Pharmaceutical Co., Ltd. (CCPC)
• Ciron Drugs And Pharmaceuticals Pvt Ltd.
• Corden Pharma Gmbh
• Core Rx, Inc.
• Custom Pharma Services
• Daito Pharmaceutical Co., Ltd.
• Dalton Pharma Service
• Delpharm Sas
• DPT Laboratories, Ltd. (Mylan N.V.)
• Dr. Reddy’s Laboratories Ltd.
• Elpen Pharmaceutical Co. Inc.
• Elysium Pharmaceuticals Ltd.
• Euticals
• Ever Neuro Pharma Gmbh
• Evonik Industries Ag
• Famar S.A.
• Fareva Group
• Fermion Oy.
• Flamma S.P.A
• Fuji Chemical Industry Co.,Ltd
• Galenicum Health, S.L.
• GP Pharm SA
• Groupe Parima Inc.
• GSK Contract Manufacturing
• GVK Biosciences Pvt Ltd.
• HBM Pharma S.R.O
• Heraues Holding Gmbh
• Hetero Drugs
• Icrom S.P.A
• Ind-Swift Laboratories Ltd.
• Johnson Matthey Pharma Servicesinc.
• Jubilant Lifesciences
• Kern Pharma, S.L.
• Kleos Pharmaceutical Inc.
• Koak Farma Pharmaceutical
• Kolmar Korea Co., Ltd.
• Kwizda Pharma Gmbh.
• Logos Pharma
• Lonza Group Ltd
• Lotus Pharmaceutical Co., Ltd.
• LSNE Contract Manufacturing
• Madras Pharmaceuticals Pvt Ltd
• McGuff Pharmaceuticals
• Merck SAFC (Merck & Co. Inc)
• Metrics Contract Services (Mayne Pharma Inc)
• Mikart
• Mint Lifesciences Pvt Ltd.
• MSN Laboratories Pvt Ltd.
• Nautilus Pharma
• Nectar Lifesciences Ltd.
• Neolpharma Inc.
• Nextar Chempharma Solutions Ltd.
• Nextpharma Technologies Holding Limited
• Nipro Pharma Corporation
• Olon S.P.A
• Orion Pharma Ltd
• Patheon N.V. (Thermofisher)
• Pfizer Centreone (Pfizer Inc.)
• Pharma Synth Formulations Limited
• Pharmapac Uk Ltd., (Inyx, Inc.)
• Pillar5 Pharma Inc.
• Piramal Pharma Solutions
• Polpharma Sa Pharmaceutical.
• Porton Pharma Solutions Ltd.
• Recipharm Ab
• Sai Life Science Ltd.
• Sain Medicaments Pvt Ltd.
• Saneca Pharmaceutical A.S.
• Sanofi Cepia
• Scinopharm Taiwan Ltd.
• Seqens (Novacap)
• Siegfried AG
• SK Biotek Co.,Ltd
• Soigner Pharma
• Sopharma Pharma Plc.
• Stason Pharmaceuticals, Inc.
• Sterling Pharma Solutions
• Supriya Lifescience Ltd.
• Surepharma Services Ltd.
• Synokem Pharmaceuticals Ltd.
• Taj Ando Pharmaceuticals
• Temad Co.
• Tapi (Teva Pharmaceutical Industries Ltd.)
• Ubi Pharma Inc.
• Valpharma S.P.A
• Venus Pharma Gmbh
• Vivimed Labs Ltd
• Wockhardt Ltd.
• Woodfield Pharmaceutical Llc
• Wuxi Sta Pharmaceutical (Wuxi Apptec+Sta Pharmaceutical)
• Yash Pharma Laboratories Pvt Ltd.
• Zach System (Zambon Company S.P.A.)
• ZCL Chemicals Ltd
• Zhejiang Hisun Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/ltjhvl/pharmaceutical?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Pharmaceutical
Manufacturing